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The problem with clearance
Clearance is the removal of a substance from blood, 
expressed as a volume (milliliters) over time (minutes). 
However, changes in lactate levels are the sum of ongo-
ing production and removal from the blood by excretion 
(e.g., urine, sweat) and its metabolism (e.g., uptake by 
cells as a direct source of energy, conversion to glucose 
by the liver). To talk about “lactate clearance” [1] when 
actually describing a decrease in blood level is wrong and 
misleading. Following the review of 96 studies, Vincent 
et al. [1] concluded that given recent evidence, measure-
ments every 1–2  h would give clinically relevant data 
about the decrease in lactate levels.
Lactate levels: production versus clearance
In clinical practice the change in lactate levels over time 
is thought to primarily reflect a change in production. As 
increased levels are generally associated with circulatory 
dysfunction, we often see a decrease in lactate levels as 
associated with an improvement in circulatory status and 
hypothesize (but cannot prove) decreased production. 
However, as true clearance in both stable septic patients 
and septic shock animals is significantly decreased in 
shock states, ongoing hyperlactatemia or even a rise in 
lactate levels may reflect decreased clearance rather than 
an increase in production of lactate [2, 3]. This is typically 
seen in the presence of shock with associated ischemic 
hepatitis. In addition, the complex inter- and intracellular 
metabolism of lactate makes our understanding of lactate 
physiology in shock extremely limited (see Sect. “Lactate 
as a substrate”).
Lactate and glucose metabolism
As lactate is a normal product of glucose and pyru-
vate metabolism, any increase in glucose metabolism or 
decrease in pyruvate metabolism will increase lactate 
generation and, in some cases, levels, even in the pres-
ence of adequate tissue oxygenation (as seen with epi-
nephrine infusion). In sepsis, the inflammatory response 
appears associated with an increase in glycolysis and 
impaired pyruvate dehydrogenase (the enzyme critical 
for pyruvate entry into the Krebs cycle). Thus, cytoplas-
mic pyruvate increases with greater lactate formation 
but preserved pyruvate to lactate ratio, and lactate lev-
els rise. In this way, the relationship of increased lac-
tate production with tissue hypoxia as its possible source 
is confounded by the stress response that increases glu-
cose metabolism and lactate generation [4]. In addition, 
although lactate levels can be significantly decreased 
by improving its metabolism by the administration of 
dichloroacetate, this will not result in improved survival 
as it does not address the root cause [5]. The same might 
apply to the correction of acidosis in the presence of 
increased lactate levels as the relationship between pH, 
anaerobic glycolysis, and lactate levels is not fully under-
stood and is likely to be complex [6, 7].
Lactate as a substrate
Just like glucose, lactate may also serve as a substrate for 
metabolism. Especially in stress (such as sepsis), lactate, 
through several “shuttles”, provides a source of cellu-
lar energy. The first is the organ-to-organ lactate shut-
tle. Lactate released by muscle is taken up by the liver 
to enter the Cori cycle to generate glucose, which then 
through glycolysis may generate lactate depending on 
liver bioenergetics. In addition, lactate may be metabo-
lized by the kidneys, accounting for up to 50% of total 
lactate metabolism. The second is the cell-to-cell lactate 
shuttle. This shuttle appears particularly important in 
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the brain, where lactate can become a more important 
energy substrate than glucose [8]. Lactate is transported 
from astrocytes into neurons by dedicated transporters 
and then transformed into pyruvate by lactate dehydro-
genase type  1. Pyruvate then enters the Krebs cycle to 
produce ATP. The third is the intracellular shuttle where 
lactate, generated by glycolysis in the cytoplasm, is used 
through mitochondrial membrane shuttles to increase 
the concentration of reduced NAD (NADH), which pro-
vides a proton gradient to generate energy by the electron 
transport chain.
Lactate and liver dysfunction
The liver, which is responsible for 60% of systemic lactate 
metabolism, is a vulnerable organ during sepsis-related 
acute circulatory dysfunction. The contribution of the 
liver to persistent hyperlactatemia might be much higher 
than previously thought, and the mechanisms are prob-
ably multifactorial. Without doubt, hepatosplanchnic 
ischemia could contribute in some cases especially in, but 
not limited to, severe septic shock [9]. On the other hand, 
early and severe impairment of exogenous lactate clear-
ance not related to liver hypoperfusion has been shown 
in experimental conditions [3].
Lactate concentration in resuscitation fluids
Intravenous administration of lactated Ringer’s solution 
does not seem to increase circulating lactate concen-
trations in hemodynamically stable adults, nor worsen 
metabolic acidosis during an infusion of 1  L in 60  min 
[10]. Only when infusing large volumes (180 mL/kg/h) do 
lactate levels rise significantly [11]. On the contrary, the 
buffering effect of Ringer’s solution, with a more physio-
logic strong anion difference, might have a positive effect 
on blood pH.
Lactate and its confounders
As every increase in glucose metabolism may increase 
lactate  levels, many elements confound the clinical 
use of lactate. Best known in clinical practice is the use 
Fig. 1 Flowchart on the clinical use of increased lactate levels. ScvO2 central venous hemoglobin oxygenation, dPCO2 central venous–arterial  PCO2 
difference
of catecholamines in septic shock patients, alkalosis-
induced increases in glucose metabolism, lactate buff-
ered continuous hemofiltration, liver dysfunction, and 
lung lactate production. Also, the use of specific drugs 
has been associated with increased lactate levels (nucleo-
side reverse transcriptase inhibitors for treatment of HIV, 
metformin) as are some intoxications (ethylene glycol, 
methanol, and steroids) [4, 12].
Lactate with or without hypoperfusion vs tissue 
hypoxia
Persistent hyperlactatemia is particularly difficult to 
interpret. At least four possible pathogenic mechanisms 
might be involved: anaerobic glycolysis in hypoperfused 
territories, especially in the presence of severe micro-
circulatory abnormalities [13]; stress-related adrener-
gic-induced aerobic glycolysis; impaired hepatic lactate 
clearance; and mitochondrial dysfunction limiting pyru-
vate metabolism [14, 15]. Recognizing a clinical pattern 
of hypoperfusion-related hyperlactatemia is important 
since optimizing systemic blood flow in this setting could 
revert ongoing hypoperfusion and improve prognosis. In 
contrast, pursuing additional resuscitation in non-hypop-
erfusion-related cases might lead to the toxicity of over-
resuscitation. We recently proposed that a simultaneous 
analysis of three flow-sensitive parameters such as cen-
tral venous  O2 saturation, central venous–arterial  pCO2 
gradient (Pcv-aCO2), and peripheral perfusion (capillary 
refill time, peripheral perfusion index, skin temperature, 
mottling) might be helpful in suggesting the presence of 
hypoperfusion in the context of hyperlactatemia [15, 16]. 
In addition to the Pcv-aCO2 one could use the Pcv-aCO2 
to arterial–venous  O2 content difference as a marker of 
tissue hypoperfusion as a cause of hyperlactatemia [17]. 
Persistent hyperlactatemia without a hypoperfusion con-
text is associated with a better prognosis and might sug-
gest non-hypoperfusion-related sources [15] (Fig. 1). 
Lactate as a marker of severity
The evidence that lactate is a marker of illness severity in 
all situations of physiological stress is overwhelming. In 
sepsis it is a powerful predictor of mortality. In the recent 
ARISE trial, data were prospectively collected on lactate 
levels at randomization [18]. Approximately, one-third of 
patients were randomized because of isolated hyperlac-
tatemia and compared with patients randomized because 
of isolated hypotension. Despite similar age and sources 
of infection, patients with isolated hyperlactatemia had 
1.7 times the risk of 90-day mortality and were less likely 
to be discharged alive form ICU and hospital. This pre-
dictive value has been recognized by the SEPSIS-3 con-
sensus definition of shock, which requires the presence of 
hyperlactatemia [19].
Lactate as a goal of what?
The complexity of lactate as a molecule, substrate, bio-
marker, energy source, component of some intravenous 
fluids, and major modulator of cellular bioenergetics dur-
ing physiological stress is formidable [20]. Such complex-
ity makes it impossible to define what goal it should be 
a marker or target of. Seeking to lower lactate levels (by 
whatever means given the multiple events that regulate 
its blood levels) has no credibility and no logic in terms 
of hemodynamics, bioenergetics, or tissue protection. 
In fact, it could make more biological sense to assist the 
natural process of lactate utilization and generation dur-
ing sepsis or during other physiological stress situations 
by administering lactate. Until we are able to define the 
goals that we wish to achieve by manipulating lactate and 
have the means of measuring whether we have achieved 
such goals or not, the idea of seeking to lower lactate by 
increasing its “clearance” in sepsis is both an illusion and 
a folly.
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